From the Department of Pediatrics and Microbiology-Immunology; and International Center for Interdisciplinary Studies of Immunology, Georgetown University Medical Center, Washington, D.C.
Allergy Asthma Proc. 2020 Nov 1;41(6):397-412. doi: 10.2500/aap.2020.41.200072. Epub 2020 Aug 14.
Following its initial description in December 2019 in Wuhan, China, coronavirus-2 (COVID-19) has rapidly progressed into a worldwide pandemic, affecting millions of lives. Although every specialty of medicine has been affected, the field of allergy/immunology holds a special place in the battle against this modern-day plague. Because of the specialized training in allergy and clinical immunology, and the familiarity with comorbid contributing conditions, the allergist/immunologist is uniquely poised to play a major role both in the delivery of specialized therapeutic procedures and practices that can improve the health of patients with COVID-19 as well as in the use of forthcoming vaccines for the prevention of its spread. The purpose of this report is to examine the current body of evidence supporting the two phases of infection and inflammation that influence the pathogenesis of COVID-19 and to provide a classification of COVID-19 disease presentations and potential therapeutic targets with which the allergist/immunologist has particular expertise. This article was based on a literature review of articles published in PubMed related to COVID-19 and the immune response, and the author's own research and clinical experiences in the field of immunology. Currently, the management of COVID-19 disease is being directed by a preventive strategy based on social distancing, quarantine, and facemasks to reduce the spread of the virus. Numerous clinical trials are being initiated to identify effective treatments for COVID-19 and are directed toward treatment of the two phases of infection and inflammation that influence the pathogenesis of COVID-19. An important resource for the allergist/immunologist is the COVID-19 Treatment Guidelines Panel (COVID-19 TGP), a National Institutes of Health sponsored panel of U.S. physicians, statisticians, and other experts, which has developed a set of continuously updated treatment guidelines intended for clinicians caring for patients during the rapidly evolving COVID-19 pandemic. COVID-19 is unique among other infectious diseases because, in many cases, the host immune inflammatory response can cause greater harm to the individual who is infected than the pathogen itself. In this report, the pathogenesis of COVID-19 and the influence it has on COVID-19 presentations is reviewed, together with recommended potential therapeutic targets and treatment recommendations.
自 2019 年 12 月在中国武汉首次描述以来,冠状病毒 2(COVID-19)迅速发展成为全球大流行,影响了数百万人的生命。尽管医学的各个专业都受到了影响,但过敏/免疫学领域在这场现代瘟疫的斗争中具有特殊地位。由于在过敏和临床免疫学方面的专业培训,以及对合并症的熟悉,过敏学家/免疫学家在提供可以改善 COVID-19 患者健康的专门治疗程序和实践以及使用即将推出的疫苗预防其传播方面具有独特的优势。本报告的目的是检查支持影响 COVID-19 发病机制的感染和炎症两个阶段的现有证据,并对 COVID-19 疾病表现和过敏学家/免疫学家具有特定专业知识的潜在治疗靶点进行分类。本文基于对在 PubMed 上发表的与 COVID-19 和免疫反应相关的文章的文献综述,以及作者在免疫学领域的研究和临床经验。目前,COVID-19 疾病的管理是基于社交距离、隔离和口罩的预防策略,以减少病毒的传播。正在启动许多临床试验来确定 COVID-19 的有效治疗方法,并针对影响 COVID-19 发病机制的感染和炎症两个阶段进行治疗。过敏学家/免疫学家的一个重要资源是 COVID-19 治疗指南小组(COVID-19 TGP),这是一个由美国国立卫生研究院赞助的美国医生、统计学家和其他专家小组,该小组制定了一套不断更新的治疗指南,旨在为在快速发展的 COVID-19 大流行期间照顾患者的临床医生提供服务。COVID-19 与其他传染病不同,因为在许多情况下,宿主免疫炎症反应对感染个体的危害比病原体本身更大。在本报告中,回顾了 COVID-19 的发病机制及其对 COVID-19 表现的影响,以及推荐的潜在治疗靶点和治疗建议。